Abstract
This patent discloses the development and therapeutic applications of novel poly-(ADP-ribose) polymerase (PARP) inhibitors featuring an isoindolinone scaffold. These isoindolinone-based PARP inhibitors represent a strategically designed class of central nerve system (CNS) cancer therapeutics that combine potent PARP inhibitory activity with enhanced blood-brain barrier (BBB) permeability.